Comprehensive assessments of immuno‐oncology drug‐based combination therapies as first‐line treatment for advanced renal cell carcinoma.

Over the last decade, there have been substantial progress in the field of systemic therapy for advanced renal cell carcinoma. Through the transition from treatment with cytokines to molecular‐targeted agents, and currently to immuno‐oncology drugs, the prognostic outcomes of patients with advanced renal cell carcinoma have been markedly improved. In particular, based on the promising outcomes of recently conducted pivotal randomized clinical trials, immuno‐oncology drug‐based combination therapy by either dual immune checkpoint inhibition or combined inhibition of an immune checkpoint and tyrosine kinase, is currently regarded as a standard of care for treatment‐naïve advanced renal cell carcinoma patients. However, insufficient data are available with respect to the selection of optimal systemic therapies for advanced renal cell carcinoma in the first‐line setting due to the lack of a head‐to‐head comparison between approved immuno‐oncology drug‐based combination therapies. In this review, therefore, we summarize interesting findings associated with first‐line combination therapies for advanced renal cell carcinoma obtained from both randomized clinical trials and real‐world clinical practices, in order to present useful guidance to help make treatment decisions for patients with treatment‐naïve advanced renal cell carcinoma. [ABSTRACT FROM AUTHOR]